恒生创新药ETF（159316）标的指数冲击三连阳，关注降息概率提升下板块修复持续性

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with key indices showing significant gains, driven by positive news regarding leading companies and favorable market conditions [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.9%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.2%, both aiming for a third consecutive day of gains [1] - The performance of the innovative drug sector is supported by the anticipated interest rate cuts by the Federal Reserve, which have increased the probability of a 25 basis point cut in December from 40% to 80.9% [1] Group 2: Company Developments - Three-Six Pharmaceutical plans to spin off its Minoxidil brand, Mandi International, for a main board listing on the Hong Kong Stock Exchange [1] - The clinical trial application for ActRIIA/B antibody JMT206 injection by CSPC Pharmaceutical has been approved for obesity treatment [1] Group 3: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first ETF-tracked index with a 100% "purity" focus on leading innovative drug companies in Hong Kong [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of the 50 largest stocks in the pharmaceutical and health sector within the Stock Connect range, covering innovative drugs and medical devices [1] - The Hang Seng Innovative Drug ETF (159316) and the Hong Kong Stock Connect Medical ETF (513200) track these indices, providing investors with opportunities to capitalize on sector recovery [1]